Bristol-Myers Squibb to acquire Mirati in $4.8 billion deal
(Reuters) -Bristol-Myers Squibb on Sunday said it will acquire cancer drugmaker Mirati Therapeutics for $58 per share in cash, representing
2023-10-09 06:50
Bristol Myers plans to double experimental treatments to expand research pipeline
Bristol Myers Squibb said on Thursday it plans to double the number of treatments it is testing in
2023-09-14 20:58